Participant flow

Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia. · Source last updated 2023-12-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   During the 12-week treatment period, participants receive a total of 5 subcutaneously (SC) doses of PF-06946860 every 3 weeks (Q3W).

   id

   FG000

   title

   PF-06946860 Q3W

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Death

   2. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Global deterioration of health status

   3. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Enrolled and not treated

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         11

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         10

      type

      Treated

   3. achievements

      1. group Id

         FG000

         num Subjects

         7

      type

      COMPLETED

   4. achievements

      1. group Id

         FG000

         num Subjects

         4

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

A total of 20 participants were screened for eligibility, of which 11 participants were enrolled into the study. A total of 10 participants were treated.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice